Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

177Lu-TLX250 · TLX250

Radiopharmaceutical · Kills target cells, directed at carbonic anhydrase IX (CAIX) (CA9) · developed by Telix Pharmaceuticals Pty

Phase 2 Most advanced trial
TLX Developer
1 Registered trials

What is 177Lu-TLX250?

177Lu-TLX250 is a radiopharmaceutical made of the girentuximab antibody carrying the lutetium-177 radioisotope via a tetraxetan chelator. The antibody targets carbonic anhydrase IX, and the drug is studied in clear cell renal cell carcinoma and other metastatic or recurrent renal cell cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TLX250, 177Lu girentuximab tetraxetan
Drug type
Radiopharmaceutical
Targets
carbonic anhydrase IX (CAIX) (CA9)
Mechanism
Kills target cells, directed at carbonic anhydrase IX (CAIX) (CA9)
Therapy area
Oncology
Developer
Telix Pharmaceuticals Pty Limited (TLX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07870746 Phase 2 ccRCC Not yet recruiting TLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ccRCCClear Cell Renal Cell Cancer (ccRCC)Renal Cell Cancer MetastaticRenal Cell Cancer, RecurrentRenal Cell Carcinoma (Kidney Cancer)Renal Cell Carcinoma (RCC)

Other drugs acting on CA9

More from Telix Pharmaceuticals Pty

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the TLX page.

Follow TLX, the company behind 177Lu-TLX250

See TLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TLX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.